See the DrugPatentWatch profile for Xalkori
What were Xalkori (crizotinib) sales like?
Public, company-level sales figures for Xalkori have largely been replaced in recent reporting by other products and by broader “on-vs-off” prescription trends. Exact sales by quarter or year aren’t included in the information provided here, so I can’t quote a specific number for “Xalkori sales” without additional source material.
If you tell me which period you mean (for example, “2022 full-year,” “last quarter,” or “since launch”) and whether you want global or a specific country/region, I can format the sales summary accordingly.
Where do Xalkori sales show up in quarterly/annual reports?
Xalkori sales are typically reported by the manufacturer in:
- Product revenue lines (or operating segment commentary) in quarterly filings.
- Annual reports where major products are broken out or discussed.
- Sales/partner statements when markets are served through collaboration arrangements.
If you share the manufacturer (historically Pfizer; also formerly depends on prior co-promotion/agreements) or a filing year/quarter, I can map where the Xalkori revenue line appears and how it’s described.
How have Xalkori sales changed over time?
Xalkori’s sales trajectory has generally been influenced by:
- Competition from newer ALK therapies and changing prescribing patterns.
- Shifts in ALK testing and treatment sequencing.
- Safety/tolerability perceptions and guideline updates.
To quantify “how much” sales changed, I need the same missing inputs as above: the timeframe and the geography, plus a source (earnings release, 10-K/20-F, analyst dataset, etc.).
What drives the market value people associate with Xalkori today?
Interest in “Xalkori sales” often comes up alongside:
- Loss of exclusivity or patent/litigation timelines (and the resulting impact on demand).
- Availability of newer-generation ALK inhibitors as standards of care.
- Geographic differences (where generics/biosimilars and payer coverage can shift volumes faster).
If you want, I can also summarize the typical drivers of revenue changes once you specify a time window and the level of detail you want (high-level trend vs. exact numbers).
Do you want current sales, historical sales, or a competitor comparison?
People searching “Xalkori sales” often want one of these:
- Current quarterly sales trend
- Historical annual revenue
- Comparison vs other ALK inhibitors (for example, in the same indication/line of therapy)
Reply with:
1) the year(s) or quarter(s),
2) global vs a country, and
3) whether you want a raw number, a trend description, or a comparison,
and I’ll produce a targeted sales-focused answer.